We examined the effect of fibroblast growth factor-2 (FGF-2) on myocardial resistance to injury when administered after the onset of ischemia, in vivo and ex vivo, and the role of FGF-2 receptors and protein kinase C (PKC). FGF-2 was injected into the left ventricle of rats undergoing permanent surgical coronary occlusion leading to myocardial infarction (MI). After 24 hours, FGF-2-treated hearts displayed significantly reduced injury, determined by histological staining and troponin-T release, and improved developed pressure compared to untreated controls. An FGF-2 mutant with diminished affinity for the tyrosine kinase FGF-2 receptor 1 (FGFR1) was not cardioprotective. FGF-2-treated hearts retained improved function and decreased damage at 6 weeks post-MI. In the ex vivo heart, FGF-2 administration during reperfusion after 30 min ischemia improved functional recovery and increased relative levels of PKC subtypes α,ε,ζ in the particulate fraction, in a chelerythrine-preventable mode; it also decreased loss of energy metabolites. We conclude that intramyocardial FGF-2 administration shortly after the onset of ischemia confers protection from acute and chronic cardiac dysfunction and damage; FGF-2 delivered during reperfusion protects from ischemia-reperfusion injury; protection by FGF-2 requires intact binding to FGFR1, and is likely mediated by PKC.
INTRODUCTION
FGF-2, a prototypical member of the larger family of heparin-binding growth factors is a multifunctional protein that stimulates cell growth, angiogenesis, affects gene expression and differentiation and protects cells from apoptosis and/or necrosis (21) . There is strong evidence that, as an angiogenic agent, FGF-2 may represent a promising new long term treatment during remodeling after myocardial infarction (MI) (48) . FGF-2, given intra-arterially or by pericardiac implantation over a 4-6 week period, has been shown to stimulate formation of collateral vessels in chronic post-MI heart and thus improve perfusion (25, 47) . Early clinical trials confirm that FGF-2 is beneficial as a long term treatment, although side effects were also noted (44) .
In addition to its long term effects on the circulatory system, FGF-2 affects adult cardiac myocytes directly; these cells express functional FGFR1 (26) and respond to FGF-2 by changes in contractility (31) and hypertrophy (40) . Furthermore, FGF-2 administered to the isolated rat or mouse heart before ischemia is clearly protective against subsequent ischemia and reperfusion injury (32) (31, 42) . The acute protective effects of FGF pretreatment are proposed to engage a preconditioning-like mechanism (17, 31) , and thus one theoretical therapeutic possibility for FGF-2 would be as an agent of primary injury prevention.
water-filled compliant balloon, connected to a pressure transducer (Stratham P23 ID) was inserted into the left ventricle via the mitral valve. Mechanical function was assessed as developed pressure (DP), end diastolic pressure (EDP), and rate of contraction/relaxation.
Functional data were acquired and analyzed using a PC based system (Harvard Apparatus, Saint Laurent, Quebec). Hearts were perfused at a constant pressure of 80 mm Hg with a modified Kreb's-Henseleit (K-H) buffer as described (31) . (a): For the ex vivo ischemiareperfusion experiments left ventricular end diastolic pressure was adjusted to 5-10 mm Hg by inflating the balloon. Global ischemia was induced by interrupting the flow under normothermic conditions. Reperfusion was achieved by reestablishing flow. At the beginning of reperfusion and using a peristaltic pump, FGF-2-supplemented (10 µg in 12 ml K-H) or standard K-H buffer was infused directly into the perfusion buffer at the point of entry to the heart. Four groups (n=6-8/group) were used. All groups (1-4) were equilibrated with K-H buffer for 30 min. Group 1 was perfused with K-H buffer for another 5 min, and then subjected to 30 min global ischemia, and 60 min reperfusion in K -H. Group 2 was subjected to 5 min of perfusion in KH buffer/chelerythrine (5 µM/L) followed by 30 min global ischemia and 60 min reperfusion in KH buffer/chelerythrine. Group 3 was perfused with K-H buffer for 5 min, subjected to 30 min ischemia, 12 min of reperfusion in K-H buffer/FGF-2 and 48 min of reperfusion in K-H. Group 4 was subjected to 5 min K-H buffer/chelerythrine, followed by 30 min ischemia, 12 min of reperfusion in K -H buffer/FGF-2/chelerythrine and 48 min reperfusion in K -H buffer/chelerythrine. (b): For assessing contractile function after permanent coronary ligation in vivo, rats were killed at 4-24 hours and 1-6 weeks post-MI and hearts placed in a Langendorff apparatus. Hearts were maintained at constant pressure of 80 mm Hg. ATP and creatine phosphate (CP) concentrations were determined as described in reference (28) . Subcellular Distribution of PKC subtypes α,ε,ζ: Cytosolic (Cyt) and Triton X-100-soluble membrane (M) fractions were obtained from hearts subjected to 30 min ischemia and 30 min of reperfusion in the presence or absence of FGF-2 exactly as described recently by (45) (n=3).
The remaining Triton X-100 insoluble (P=pellet) fractions were solubilized directly in SDS/PAGE buffer (24) . Cytosolic and total particulate fractions were also obtained from hearts treated with FGF-2 in the presence or absence of chelerythrine (n=3). The different fractions (20 µg/lane) were analyzed by SDS/PAGE and western blotting, probing or PKC subtypes α,ε,ζ, exactly as we described previously(31).
FGF-2(S) mutagenesis: The plasmid FGF-2 (S). pET19b, containing the AUG-initiated 18 kDa form of rat FGF-2, was used as the template for PCR site directed mutagenesis.The oligonucleotide primers synthesized by Bio.Synthesis Co. corresponding to sequences within FGF-2 but bearing single base pair mismatches were used for amplification of mutated subfragments in separate reactions. PCR mutagenesis was carried out in 2 steps. 1) The primer 5'-GTAGTTATTGGACTCCAGGCGTcCAAAGAAGAAACAC-3'(glu104-ala antisense strand primer), was used in combination with the FGF-2(S) sense strand primer 5'-GGATTGAGACTCCATATGGCTGCCGGCAGCATCCTTCG-3' to generate the upstream half of FGF-2 fragments and termed GluM1. The primers 5'-GTGTTTCTTCTTTGcACGCCTGGAGTCCAATAAC-3'(glu104-ala sense primer) was used in combination with a T7 terminator primer 5'-GCTAGTTATTGCTCAGCGG-3' (corresponding to vector sequences) to generate the downstream half mutated FGF-2 fragment termed GluM2.
After amplification, the PCR products were analyzed in 1% agarose gels and isolated for subsequent PCR. 2). To generate the full length mutant FGF-2 cDNA, the subfragments GluM1 and GluM2 were mixed and followed by PCR amplification through 2 cycles at 95 C for 1min, 60 C 1min, 72 C 10 min in 30µl reaction with10mM Tris pH8. hours post MI, animals were killed, hearts removed and degree of myocardial damage assessed using the tetrazolium method for staining, followed by morphometric analysis. Results are shown in Fig.1 . Injection of wt.FGF-2 (2 µg) resulted in significantly smaller infarct area compared to saline -injected controls at both time points. Reduced wt.FGF-2 dose (0.2 µg) also produced smaller infarct area compared to saline, although the effect was smaller than with the higher wt.FGF-2 dose. The extent of infarction in the group injected with mt.FGF-2 (2 µg) was similar to the saline-treated group, signifying no protection.
The degree of myocardial damage was also examined by determining relative levels of cardiac TnT present in the serum. We used Western blot analysis of total serum proteins, probed with an anti-cardiac TnT antibody; incubation without the primary antibody was used as control for non-specific binding. Relative TnT levels were estimated by densitometry, and found to be significantly lower (by about 40%) in the blood of wt.FGF-2 treated rats compared to saline treated controls (P<0.05, n=6). As seen in Fig.1B and C, the effects of wt.FGF-2 were dependent on the dose, and TnT levels in the plasma from mt.FGF-2-treated rats were not significantly different than those of untreated controls.
To examine retention and localization of wt or mt FGF-2 in the heart, the injected, left ventricular ischemic myocardium was sectioned 6 hours after surgery and examined for infarcted hearts had a significantly reduced DP of 53.77 ± 2.30 mm Hg, indicating that the heart retained only 61% of contractile function (P<0.05, n=6). At the same preload, the DP of FGF-2-treated infarcted hearts reached 72.24 ± 4.55 mm Hg, significantly higher than that of the salinetreated hearts, indicating that now the heart retained 82% of its function (P<0.05, n=6) . Positive as well as negative dP/dt at a preload of 5 mmHg was also significantly improved in FGF-2-treated hearts. Significant improvement of DP recovery in the FGF-2-treated hearts was seen under all preload conditions tested.
Cardiac function was also assessed one week after coronary ligation and treatment with FGF-2 or vehicle. At 5 mm preload, saline-treated infarcted hearts (n=5) displayed a DP of 52.22 ± 2.11 mm Hg, while FGF-2-treated infarcted hearts (n=5) had a significantly (P<0.05)
higher DP of 63.92 ± 3.52 mm Hg (representing a 22% increase in function). Even at 6 weeks post-MI, FGF-2-treated, infarcted hearts displayed increased DP (by about 35%), compared to saline-treated controls, at the preload range tested (0-7.5 mm Hg) (Fig.4A, P<0 .05, n=4).
The extent of myocardial loss was also assessed at 6 weeks post MI: Scar tissue was significantly reduced (by 38%) in the FGF-2-treated hearts compared to saline treated controls (Fig.4A, P<0 .05, n=4).
Effect of FGF-2 administered during reperfusion on recovery. Involvement of PKC
The in vivo study examined the effect of FGF-2 on ischemic, non-reperfused myocardium. Current strategies for effective management of an acute ischemic episode require prompt tissue reperfusion. While restoration of blood flow is considered essential for salvaging myocardial function, it has been associated with a degree of exacerbation of myocardial injury (36) . To investigate whether FGF-2 would be protective when administered during reperfusion we used the ex vivo heart model of 30 min of global ischemia followed by 60 min of reperfusion, as previously described (31, 32) . In this model, FGF-2 is infused into the reperfusion medium during the first 12 min of reperfusion. A schematic representation of the different groups used for these studies is shown in Fig.5 .
At 20-60 min of reperfusion, recovery of DP in group 1 (untreated controls) and group 3 (FGF-2-treated) was at 47% (±4) and 74% (± 3), respectively, of corresponding preischemic values (Fig.6A) . The FGF-2 group furthermore displayed only a 4 -fold increase in EDP, significantly less than the 7 -fold increase in the control group (Fig.6B) . It would appear therefore that FGF-2, delivered during early reperfusion, induced a significant improvement of contractile function parameters (P<0.05).
We then used the water-soluble, PKC inhibitor chelerythrine to examine if PKC activation was required for the manifestation of FGF-2 cardioprotection of ischemic myocardium during reperfusion. Pre-treatment of hearts with chelerythrine alone, followed by continuous presence of chelerythrine during reperfusion (Group 2) produced no discernible difference in contractile recovery (DP=50 ±2%) compared to untreated controls (DP=47% ± 4%) (Fig.6A) ; fold-increase in EDP was similarly not significantly different to that of group 1 (Fig.6B ). When FGF-2 was administered to the chelerythrine pretreated hearts (Group 4) it no longer improved contractile recovery: DP in the chelerythrine/FGF-2 group reached 52 ± 4% of preischemic values, significantly reduced compared to the FGF-2-treated group (74 ±3%, P<0.05), and not significantly different than either untreated controls, or the chelerythrine pretreated group (Fig.6C) . Similarly, the FGF-2-induced improvement in fold-increases in EDP was completely prevented in the chelerythrine pretreated hearts (Fig.6D ).
To determine whether FGF-2 affected the subcellular distribution of PKC subtypes α,ε and ζ, we examined their relative levels in the cytosolic, Triton-soluble membrane-(M) , and
Triton-insoluble-(P) fractions. The M and P fractions represent further fractionation of the 'particulate' fraction remaining after removal of cytosolic proteins and are enriched in membrane and cytoskeletal / intercalated disc proteins respectively. As shown in Fig.7 , FGF-2 significantly decreased the relative levels of all PKC subtypes tested in the cytosol. This was accompanied by significant increases in the relative levels of PKCα in the M fraction and those of PKCε and ζ in the P fraction. We also examined whether chelerythrine affected relative levels of PKC subtypes in FGF-2-treated hearts (Fig.7) . Relative levels of all PKCs in the cytosol of chelerythrine-FGF-2-treated hearts were significantly higher than those in FGF-2-only treated samples. Conversely, relative levels of all PKCs in the 'particulate' fraction (combined M and P fraction) of chelerythrine-FGF-2-treated hearts was significantly lower than in the FGF-2-treated samples (Fig.7B ). This is in agreement with previous studies that have shown chelerythrine to prevent the translocation of PKC in cardiomyocytes (11) . Our data show that, in hearts reperfused after ischemia, FGF-2 induced redistribution of PKCs from cytosolic to particulate fractions in a chelerythrine-preventable mode.
We examined the effect of FGF-2 on ATP and CP levels (Fig.8) , after 60 min reperfusion. Untreated hearts subjected to I-R had significantly reduced levels of both ATP and CP, at 43% and 58% of pre-ischemic values, respectively. ATP levels in FGF-2 treated hearts were significantly higher than that of untreated hearts, representing 67% of pre-ischemic values (P<0.05, n=6). CP levels in FGF-2-treated hearts were also significantly higher than those of untreated hearts and were not significantly different than preischemic controls (P<0.05, n=6).
Increased levels of energy metabolites in the FGF-2-treated hearts would be consistent with decreased myocardial damage.
DISCUSSION
The need for effective treatments that reduce the extent of an evolving myocardial infarction cannot be understated. No clinically useful agents capable of protecting the ischemic myocardium, in the presence or absence of re-establishment of flow, are currently available (49) . We therefore examined whether FGF-2 has a protective effect on the ischemic myocardium in two different experimental models: In vivo, FGF-2 was injected directly to the ischemic ventricle during irreversible surgical coronary ligation, to examine its ability to salvage ischemic tissue from damage. In the Langendorff perfused heart, FGF-2 was administered during the reperfusion phase, to examine its effects on dysfunction and loss of energy metabolites subsequent to ischemia and reperfusion. In addition, we examined the participation of specific elements of the FGF-2 signal transduction pathway in relation to cardioprotection. We To our knowledge, FGF-2 is the only agent identified to-date that exerts protection when administered locally to the ischemic heart, and also during reperfusion . Our findings extend and are in broad agreement with previous reports of cardioprotection by systemic administration of FGF-1 (a factor belonging to the same family of heparin binding growth factors as FGF-2) or FGF-2, in vivo (4) (5). Others, using intra-coronary infusion of FGF-2 in a canine model, reported that FGF-2 significantly limited myocardial necrosis after acute coronary occlusion (15) .
A significant difference with our approach is that in the in vivo model we used local intramyocardial delivery to avoid overall systemic involvement, including potential side effects, but also any uncertainty as to the direct i nvolvement of heart muscle itself. In addition, we adressed the duration of the beneficial effects by assessing the hearts up to several weeks from treatment.
Injected FGF-2 induced protection of cardiomyocytes in vivo as indicated by infarct size estimates as well as relative TnT plasma levels (Fig.1) . FGF-2 was clearly retained by the myocardium and localized around myocytes, indicating its potential to directly influence these cells. We have previously shown that FGF-2 injected into the myocardium triggers tyrosine phosphorylation in the cardiac myocyte (26), a finding consistent with in situ activation its tyrosine kinase (TK) FGFR1.
The biological effects of extracellular FGF-2 are mediated by binding to plasma membrane TK receptors (FGFR1-4) and heparan sulphate proteoglycan (HSPG) 'low' affinity sites (27) . The HSPG sites are considered to allow and/or facilitate binding to the TK receptors; they may also mediate independent signaling events (38) . To examine whether the cardioprotective effects of FGF-2 required intact binding to FGFR1 (the only FGF-2 receptor expressed in adult rodent myocardium (18, 33) (10) (26)) we used mt.FGF-2. Rat mt.FGF contains a substitution of glutamine-104 with an alanine residue, equivalent to the glutamine-96 mutation on human FGF-2. This mutation produces FGF-2 that binds to the 'low affinity' HSPG sites with unchanged affinity, but has diminished affinity for FGFR1(50). Our own characterization confirmed that while mt.FGF-2 was retained by the heart (presumably by binding to HSPGs of the basement membrane and the extracellular matrix), and localized around cardiomyocytes (Fig.2 ) in a manner identical to wt.FGF-2, it was unable to displace wt.( 125 I-) FGF-2 from the high affinity plasma membrane sites (unpublished observations).
Mt.FGF-2 had no cardioprotective properties. Thus it would appear that the effect of FGF-2 in the heart is dependent on its ability to bind to FGFR1, and that binding to HSPG sites is not sufficient for cardioprotection. Although FGFR1 is known to mediate cardiac growth in development, its role in the adult myocardium has been less clear. We propose that FGFR1 can mediate FGF-2 cardioprotection of the ischemic myocardium in vivo.
FGF-2 was injected in the middle of the lower half (nearer to the apex) of the left ventricle, an area that was rendered ischemic as judged by its changed color and development of akinesis after occlusion. Exogenous FGF-2 localized in association with viable myocardium surrounding the infarcted region, as well as with irreversibly injured myocytes (Fig.2) . It is therefore presumed that FGF-2 exerted its protection on cells suffering intermediate levels of Unlike FGF-1 which has been reported to prevent ischemia-reperfusion-induced apoptosis (6), we do not think it likely that FGF-2 protection in our in vivo system involved effects on apoptosis. Examination of several sections per heart revealed a negligible number of TUNEL positive nuclei in muscle or non-muscle cells (unpublished observations), in agreement with reports linking apoptosis predominantly to reperfusion events (20) .
FGF-2 administered during reperfusion is protective against ischemia-reperfusion injury; involvement of PKC: In our previous studies where FGF-2 was administered to isolated rat hearts before ischemia, we noted that FGF-2 was retained by the myocardium even after 30 min of ischemia followed by 1 hour of reperfusion (32) . As a result, FGF-2 might be expected to continue exerting effects on myocytes during the reperfusion phase. Indeed, as presented here, FGF-2 administration during the reperfusion stage elicited a significant improvement in recovery of function. The extent of this recovery was similar to that induced by FGF-2 given before ischemia. Both pre-ischemic (31, 32) and post-ischemic (Fig.2) administration of FGF-2 resulted in hearts displaying a 1.6-fold increase in developed pressure over that of untreated controls, after 30 min ischemia and 60 min of reperfusion. Thus, it would appear that irrespectively of whether it induces a preconditioning response in non-ischemic cells, FGF-2 is cardioprotective when administered during reperfusion on ischemic myocytes.
Increased contractile recovery, accompanied by increased levels of energy metabolites in the FGF-2-treated ex vivo ischemic hearts are consistent with decreased myocyte injury.
Preservation against contractile dysfunction or 'stunning' (14) or direct effects on energy metabolism may also have contributed to improved functional recovery and merit further investigation.
To address mechanism of FGF-2 cardioprotection during reperfusion we examined the role of PKC. PKC, in particular the ε-isoform, is known to mediate the early and late preconditioning responses and cardioprotection (35, 37, 43) . FGF-2-triggered signal transduction in cardiomyocytes includes FGFR1-mediated activation of PLC and PKCε in cardiomyocytes (9, 31) . In the present investigation, involvement of PKC signaling was supported by the FGF-2-induced redistribution of PKC to particulate compartments (Fig.7) . A recent paper showed that PKC activity/redistribution during reperfusion serves to preserve myocytes from reperfusion injury (45) . PKC activation by FGF-2 during reperfusion therefore would be expected to enhance cardiac resistance to injury,exactly as we found (Fig.6) . Inhibition of FGF-2-induced, (a), cardioprotection (Fig.6) , and (b), PKC translocation (Fig.7B) by chelerythrine supports the notion that PKC activation during reperfusion is required for the cardioprotective effects of FGF-2.
FGF-2 affected all three PKC subtypes examined, representing all three classes of PKC.
Since there is evidence that PKCε mediates protection during reperfusion (45) , it is likely that at least this subtype contributed to the protective effect of FGF-2. It is of interest that FGF-2 caused translocation of PKCε to the P fraction, containing the majority of at least one of its established targets and interacting proteins, the gap junction protein connexin-43 (9) (34) (2).
We have shown previously that FGF-2 stimulates PKCε-dependent phosphorylation of the gap junction protein connexin-43, leading to decreased coupling between cardiomyocytes (8, 9).
Myocyte uncoupling caused by other agents such as anesthetics is considered to be protective by preventing the spreading of hypercontracture via gap junctions (12, 39) . We therefore speculate that FGF-2 cardioprotection during reperfusion may include PKC-mediated effects on cardiac gap junctions.
In conclusion, FGF-2 is an excellent candidate for secondary prevention of evolving ischemic myocardial damage, at least in our animal model. The safety and efficacy of intramyocardial and/or local delivery of therapeutic agents is the subject of intense interest (44) (23); recent studies using pig models indicated that fluorescopy-guided intramyocardial injection is a feasible and safe procedure (13) . It is thus reasonable to suggest that acute 'protein therapy' using FGF-2 formulations may not be technically forbidding. Assuming safety issues have been fully addressed, FGF-2 might be delivered intramyocardially; by catheterization; through the coronary artery;during performance of angiograms; and last, but not least, as an additional treatment during re-establishment of blood flow. ischemia-reperfusion injury of the ex vivo heart (as also described in the methods section). 
